Immune suppression within the tumor microenvironment (TME) has been demonstrated as an integral barrier to the efficacy of immunotherapy, impairing the ability of tumor-specific CD4+ or CD8+ T cells to respond with maximal activation or effector function (5–7). This evidence concerns the gene CD8A and neoplasm.